Gut microbiota as a regulator of energy homeostasis and ectopic fat deposition: Mechanisms and implications for metabolic disorders

Current Opinion in Lipidology

Volumn 21, Issue 1, 2010, Pages 76-83

  Musso, Giovanni ^a   Gambino, Roberto ^b   Cassader, Maurizio ^b  

^a GRADENIGO HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Endotoxin; Energy homeostasis; Microbiota; NAFLD; Obesity

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ANTIBIOTIC AGENT; ENDOTOXIN; FATTY ACID; FATTY ACID SYNTHASE; GLUCAGON LIKE PEPTIDE 2; LIPOPOLYSACCHARIDE; PREBIOTIC AGENT; PROBIOTIC AGENT; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TOLL LIKE RECEPTOR 4;

DIABETES MELLITUS; DIET; ENERGY METABOLISM; FATTY ACID BLOOD LEVEL; FATTY ACID OXIDATION; FATTY ACID TRANSPORT; FIBROGENESIS; FOOD INTAKE; HOMEOSTASIS; HUMAN; INNATE IMMUNITY; INTESTINE FLORA; LIPID STORAGE; METABOLIC DISORDER; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN SECRETION; REVIEW; SATIETY;

ANIMALS; DIGESTIVE SYSTEM; ENERGY METABOLISM; FATTY ACIDS; HOMEOSTASIS; HUMANS; METABOLIC DISEASES; METAGENOME;

ANIMALIA;

EID: 77649125721     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e3283347ebb     Document Type: Review

References (46)

1. Backhed F, Ding H, Wang T, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA 2004; 101:15718-15723.
2. Musso G,Gambino R,Cassader M. Recent insights into hepatic lipid metabolism in nonalcoholic fatty liver disease (NAFLD). Prog Lipid Res 2009; 48:1-26.
3. Ley RE, Backhed F, Turnbaugh P, et al. Obesity alters gut microbial ecology. Proc Natl Acad Sci USA 2005; 102:11070-11075.
4. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature 2006; 444:1022-1023.
5. Turnbaugh PJ, Ley RE, Mahowald MA, et al. An obesity-associated gut micro-biome with increased capacity for energy harvest. Nature 2006; 444:1027-1031.
6. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007; 56:1761-1772.
7. Hildebrandt MA, Hoffman C, Sherrill-Mix SA. High-fat diet determines the composition of the murine gut microbiome independently of obesity. Gastro enterology 2009. doi: 10.1053/j.gastro.2009.08.042.
8. Backhed F, Manchester JK, Semenkovich CF, Gordon JI. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci USA 2007; 104:979-984.
9. Cani PD, Delzenne NM. The role of the gut microbiota in energy metabolism and metabolic disease. Curr Pharm Des 2009; 15:1546-1558.
10. Lu YC, Yeh WC, Ohashi PS. LPS/TLR4 signal transduction pathway. Cytokine 2008; 42:145-151.
11. Cani PD, Bibiloni R, Knauf C, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008; 57:1470-1481.
12. Musso G, Gambino R, Cassader M. Nonalcoholic fatty liver disease from pathogenesis to management: an update. Obesity Rev 2009 (in press). doi: 10.1111/j.1467-789X.2009.00657.
13. Thuy S, Ladurner R, Volynets V, et al. Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. J Nutr 2008;138:1452-1455.
14. Farhadi A, Gundlapalli S, Shaikh M, et al. Susceptibility to gut leakiness: a possible mechanism for endotoxaemia in nonalcoholic steatohepatitis. Liver Int 2008; 28:1026-1033.
15. Miele L, Valenza V, La Torre G, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009;49:1877-1887.
16. Sabate JM, Jouet P, Harnois F, et al. High prevalence of small intestinal bacterial overgrowth in patients with morbid obesity: a contributor to severe hepatic steatosis. Obes Surg 2008; 18:371-377.
17. Ruiz AG, Casafont F, Crespo J, et al. Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of nonalcoholic steatohepatitis. Obes Surg 2007; 17:1374-1380.
18. Rivera CA, Adegboyega P, van RN, Tagalicud A, et al. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of nonalcoholic steatohepatitis. J Hepatol 2007; 47:571-579.
19. Nair S, Cope K, Risby TH, Diehl AM. Obesity and female gender increase breath ethanol concentration: potential implications for the pathogenesis of nonalcoholic steatohepatitis. Am J Gastroenterol 2001; 96:1200-1204.
20. Cope K, Risby T, Diehl AM. Increased gastrointestinal ethanol production in obese mice: implications for fatty liver disease pathogenesis. Gastroenterology 2000; 119:1340-1347.
21. Assy N, Nasser G, Kamayse I, et al. Soft drink consumption linked with fatty liver in the absence of traditional risk factors. Can J Gastroenterol 2008;22:811-816.
22. Ouyang X, Cirillo P, Sautin Y, et al. Fructose consumption as a risk factor for nonalcoholic fatty liver disease. J Hepatol 2008; 48:993-999.
23. Spruss A, Kanuri G, Wagnerberger S, et al. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology 2009; 50:1094-1104.
24. Bergheim I, Weber S, Vos M, et al. Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin. J Hepatol 2008; 48:983-992.
25. Seki E, De Minicis S, Osterreicher CH, et al. TLR4 enhances TGF-p signaling and hepatic fibrosis. Nature Med 2007; 13:1324-1332.
26. Velayudham A, Dolganiuc A, Ellis M, et al. VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice. Hepatology 2009; 49:989-997.
27. Terpstra AHM. Effect of conjugated linoleic acid on body composition and plasma lipids in humans: an overview of the literature. Am J Clin Nutr 2004; 79:352-361.
28. LeeK, PaekK, Lee HY, et al. Antiobestity effect of trans-10, cis-12-conjugated linoleic acid-producing Lactobacillus plantarum PL62 on diet-induced obese mice. J Appl Microbiol 2007; 103:1140-1146.
29. Wall R, Ross RP, Shanahan F, et al. Metabolic activity of the enteric microbiota influences the fatty acid composition of murine and porcine liver and adipose tissues. Am J Clin Nutr 2009; 89:1393-1401.
30. Kalliomaki M, Collado MC, Salminen S, Isolauri E. Early differences in fecal microbiota composition in children may predict overweight. Am J Clin Nutr 2008; 87:534-538.
31. Creely SJ, McTernan PG, Kusminski CM, et al. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab 2007; 292:E740-E747.
32. ErridgeC, AttinaT, SpickettCM, Webb DJ. A high-fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation. Am J Clin Nutr 2007; 86:1286-1292.
33. Anderson PD, Mehta NN, Wolfe ML, et al. Innate immunity modulates adipokines in humans. J Clin Endocrinol Metab 2007; 92:2272-2279.
34. Amar J, Burcelin R, Ruidavets JB, et al. Energy intake is associated with endotoxemia in apparently healthy men. Am J Clin Nutr 2008; 87:1219-1223.
35. Ghoshal Sarbani, Witta J, Zhong J, et al. Chylomicrons promote intestinal absorption of lipopolysaccharides. J Lipid Res 2009; 50:90-97.
36. Cani PD, Possemiers S, Van de Wiele T, et al. Changes in gut microbiota control inflammation in GLP-2-driven improvement of gut permeability obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut (published online 24 Feb 2009). doi: 10.1136/gut.2008. 165886.
37. Hsieh J, Longuet C, Maida A, et al. Glucagon-like peptide-2 increases intestinal lipid absorption and chylomicron production via CD36. Gastroenterology 2009; 137:997-1005.
38. Wang Z, Xiao G, Yao Y, et al. The role of bifidobacteria in gut barrier function after thermal injury in rats. J Trauma 2006; 61:650-657.
39. Griffiths EA, Duffy LC, Schanbacher FL, et al. In vivo effects of bifidobacteria and lactoferrin on gut endotoxin concentration and mucosal immunity in Balb/ c mice. Dig Dis Sci 2004; 49:579-589.
40. Membrez M, Blancher F, Jaquet M, et al. Gut microbiota modulation with norfloxacin and ampicillin enhances glucose tolerance in mice. FASEB J 2008; 22:2416-2426.
41. Cani PD, Neyrinck AM, Fava F, et al. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 2007; 50:2374-2383.
42. Li Z, Yang S, Lin H, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003; 37:343-350.
43. Cani PD, Lecourt E, Dewulf EM, et al. Gut microbiota fermentation of prebiotics increases satietogenic and incretin gut peptide production with consequences for appetite sensation and glucose response after a meal. Am J Clin Nutr. 2009 [Epub ahead of print].
44. Nilsson AC, Ostman EM, Holst JJ, Bjorck IM. Including indigestible carbohydrates in the evening meal of healthy subjects improves glucose tolerance, lowers inflammatory markers, and increases satiety after a subsequent standardized breakfast. J Nutr 2008; 138:732-739.
45. Parnell JA, Reimer RA. Weight loss during oligofructose supplementation is associated with decreased ghrelin and increased peptide YY in overweight and obese adults. Am J Clin Nutr 2009; 89:1751-1759.
46. Solga SF, Buckley G, Clark JM. The effect of a probiotic on hepatic steatosis. J Clin Gastroenterol 2008; 42:1117-1118.